Danaher(US:DHR) ZACKS·2025-10-21 17:41Core Insights - Danaher Corporation's (DHR) third-quarter 2025 adjusted earnings were $1.89 per share, exceeding the Zacks Consensus Estimate of $1.71, marking a 10.5% year-over-year increase [1][9] - The company reported net sales of $6.05 billion, surpassing the consensus estimate of $6.00 billion, with a year-over-year growth of 4.5% across all segments [1][9] - Core sales increased by 3% year over year, with foreign-currency translations contributing positively by 1.5% [1] Segmental Performance - Life Sciences segment revenues reached $1.79 billion, a 0.5% increase year over year, although core sales decreased by 1% [2] - Diagnostics segment revenues totaled $2.46 billion, up 4% year over year, with core sales increasing by 3.5% [3] - Biotechnology segment revenues were $1.80 billion, reflecting a 9% year-over-year increase, with core sales rising by 6.5% [4] Margin and Profitability - Danaher's cost of sales rose by 5.5% year over year to $2.53 billion, while gross profit increased by 3.6% to $3.52 billion, resulting in a gross margin of 58.2% [5] - Operating profit surged by 20.5% year over year to $1.15 billion, with operating margin expanding to 19.1% from 16.5% [6] Balance Sheet and Cash Flow - At the end of the third quarter, Danaher had cash and equivalents of $1.53 billion, down from $2.08 billion at the end of 2024, with long-term debt increasing to $16.8 billion [7] - The company generated net cash of $4.30 billion from operating activities in the first nine months of 2025, compared to $4.67 billion in the same period last year [8] Future Outlook - For the upcoming quarter, Danaher anticipates adjusted core sales from continuing operations to increase in the low single digits year over year, with expected adjusted earnings between $7.70 and $7.80 per share [10]